Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Paul Stenson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Dec 16
Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group. Alexium International Group Limited (ASX:AJX) acquired Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. The consideration consists of common equity of Alexium International Group Limited to be issued for common equity of Microtek Laboratories, Inc.
Alexium International Group Limited (ASX:AJX) completed the acquisition of Microtek Laboratories, Inc. from CAVU Group on December 15, 2025. Tillkännagivande • Dec 15
Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million. Alexium International Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.765987 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,127,664,547
Price\Range: AUD 0.006
Transaction Features: Rights Offering Tillkännagivande • Oct 22
Alexium International Group Limited, Annual General Meeting, Nov 21, 2025 Alexium International Group Limited, Annual General Meeting, Nov 21, 2025. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000 Australia Tillkännagivande • Aug 04
Alexium International Group Limited Announces Resignation of Bob Brookins as Chief Technology Officer and Executive Director, Effective August 4, 2025 Alexium International Group Limited announces that the Company's Chief Technology Officer and Executive Director, Dr Bob Brookins, has given notice of his intention to resign his roles after over 10 years of service. After completion of his three months notice period, Dr Brookins will become a consultant to the Company supporting Alexium's Technical Team which will now be led by Mr. Nick Leitner. Dr Brookins's resignation from Alexium's Board of Directors will be effective from August 4. Tillkännagivande • Oct 18
Alexium International Group Limited, Annual General Meeting, Nov 20, 2024 Alexium International Group Limited, Annual General Meeting, Nov 20, 2024. Location: at the offices of pwc, level 17, one international towers, barangaroo nsw 2000. Australia Reported Earnings • Aug 30
Full year 2024 earnings released Full year 2024 results: Revenue: US$5.89m (down 18% from FY 2023). Net loss: US$2.76m (loss narrowed 6.4% from FY 2023). New Risk • Aug 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.58m (US$8.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (140% increase in shares outstanding). Market cap is less than US$10m (€7.58m market cap, or US$8.36m). Board Change • Jul 11
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Carl Dennis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • May 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 139% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-US$3.1m). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€11.5m market cap, or US$12.4m). New Risk • May 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-US$3.1m). Market cap is less than US$10m (€6.44m market cap, or US$6.92m). Minor Risk Shareholders have been diluted in the past year (47% increase in shares outstanding). Reported Earnings • Feb 29
First half 2024 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1H 2023) First half 2024 results: US$0.003 loss per share (improved from US$0.004 loss in 1H 2023). Revenue: US$2.77m (down 20% from 1H 2023). Net loss: US$1.96m (loss narrowed 17% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. New Risk • Dec 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€6.11m market cap, or US$6.71m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Tillkännagivande • Oct 26
Alexium International Group Limited Announces Resignation of Stephen Cheney as Non-Executive Director, Effective 1 November 2023 Alexium International Group Limited announced that Brigadier General Stephen Cheney, USMC (Ret) has advised the Company of his intention to resign as Non-Executive Director of Alexium, effective 1 November 2023. Mr. Cheney has been a Non-Executive Director of Alexium since April 2015 and has served on the Company's Audit, Nomination & Remuneration, and Risk Committees. New Risk • Oct 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.5m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-US$983k). Market cap is less than US$10m (€7.94m market cap, or US$8.42m). Minor Risk Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Tillkännagivande • Sep 27
Alexium International Group Limited, Annual General Meeting, Nov 15, 2023 Alexium International Group Limited, Annual General Meeting, Nov 15, 2023, at 10:30 AUS Eastern Standard Time. Location: offices of Grant Thornton, Level 17, 383 Kent Street, 2000 Sydney New South Wales Australia Agenda: To consider the election of director. Reported Earnings • Aug 25
Full year 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in FY 2022) Full year 2023 results: US$0.005 loss per share (in line with FY 2022). Revenue: US$7.21m (down 12% from FY 2022). Net loss: US$2.95m (loss narrowed 12% from FY 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 26
First half 2023 earnings released First half 2023 results: Revenue: US$3.44m (down 35% from 1H 2022). Net loss: US$2.37m (loss widened 22% from 1H 2022). Board Change • Nov 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Managing Director Billy Blackburn was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
Full year 2022 earnings released: US$0.005 loss per share (vs US$0.002 loss in FY 2021) Full year 2022 results: US$0.005 loss per share (down from US$0.002 loss in FY 2021). Revenue: US$8.17m (up 12% from FY 2021). Net loss: US$3.36m (loss widened 133% from FY 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 01
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: US$0.003 loss per share (vs US$0.003 loss in 1H 2021). Revenue: US$5.28m (up 46% from 1H 2021). Net loss: US$1.95m (loss widened 8.9% from 1H 2021). Revenue exceeded analyst estimates by 176%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 28
Full year 2021 earnings released: US$0.002 loss per share (vs US$0.013 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$7.28m (up 20% from FY 2020). Net loss: US$1.45m (loss narrowed 76% from FY 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 26
First half 2021 earnings released: US$0.003 loss per share (vs US$0.012 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: US$3.61m (up 14% from 1H 2020). Net loss: US$1.79m (loss narrowed 59% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. 
